FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:59-60 January 7, 1999 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Narod, S. A.

To the Editor: Narod and colleagues (Aug. 13 issue)¹ suggest that oral-contraceptive therapy reduces the risk of ovarian cancer among women with mutations in the BRCA1 or BRCA2 gene. However, some possible biases should be considered.

First, the characteristics of the 207 women with ovarian cancer and the 161 control women were not similar, in that all of the patients had a BRCA1 or BRCA2 mutation but only 53 of the 95 women in the control group who were tested were carriers of the same mutations as their sisters. Even if the 66 control women who were not tested for . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.